Latin America Pharmaceutical Cdmo Market Size & Outlook
Latin America pharmaceutical cdmo market, 2018-2030 (US$M)
Related Markets
Latin America pharmaceutical cdmo market highlights
- The Latin America pharmaceutical cdmo market generated a revenue of USD 14,157.3 million in 2023.
- The market is expected to grow at a CAGR of 6.8% from 2024 to 2030.
- In terms of segment, api was the largest revenue generating product in 2023.
- API is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Brazil is expected to register the highest CAGR from 2024 to 2030.
Latin America data book summary
| Market revenue in 2023 | USD 14,157.3 million |
| Market revenue in 2030 | USD 22,457.7 million |
| Growth rate | 6.8% (CAGR from 2023 to 2030) |
| Largest segment | Api |
| Fastest growing segment | API |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | API, Drug Product |
| Key market players worldwide | Lonza Group Ltd, Thermo Fisher Scientific Inc, Labcorp Holdings Inc, Catalent Inc, Wuxi AppTec Co Ltd, Siegfried Holding AG, Nipro Corp, Piramal Pharma Solutions, Recipharm Venture Fund, CordenPharma, Cambrex, Bushu Pharmaceuticals, Seqens |
Other key industry trends
- In terms of revenue, Latin America region accounted for 9.7% of the global pharmaceutical cdmo market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 92,961.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pharmaceutical CDMO Market Scope
Pharmaceutical CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Latin America pharmaceutical cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical cdmo market will help companies and investors design strategic landscapes.
Api was the largest segment with a revenue share of 81.01% in 2023. Horizon Databook has segmented the Latin America pharmaceutical cdmo market based on api, drug product covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing demand for pharmaceutical drugs drives the Latin America pharmaceutical CDMO market as pharmaceutical companies invest in R&D. Furthermore, the growing number of clinical trials and the burden of diseases are driving expansion in the Latin American market.
In addition, the Latin America market is expected to grow rapidly, driven by the affordability of services offered by its CDMOs and the increasing participation of emerging regional players in the pharmaceutical and biotechnology industries.
For instance, in December 2023, Acino, a pharmaceutical company based in Zurich, acquired M8 Pharmaceuticals, a biopharmaceutical company based in Mexico City. M8 specializes in licensing, marketing, and distributing medicines in Mexico & Brazil.
Reasons to subscribe to Latin America pharmaceutical cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Latin America pharmaceutical cdmo market databook
-
Our clientele includes a mix of pharmaceutical cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America pharmaceutical cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America pharmaceutical cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Latin America pharmaceutical cdmo market size, by country, 2018-2030 (US$M)
Latin America Pharmaceutical CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
